Srivastava Ruchi, Khan Arif A, Chilukuri Sravya, Syed Sabrina A, Tran Tien T, Furness Julie, Bahraoui Elmostafa, BenMohamed Lbachir
Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, California, USA.
INSERM, U1043, and CNRS, U5282, Toulouse, France.
J Virol. 2017 Jun 26;91(14). doi: 10.1128/JVI.00278-17. Print 2017 Jul 15.
Herpes simplex virus 1 (HSV-1) establishes latency within the sensory neurons of the trigeminal ganglia (TG). HSV-specific memory CD8 T cells play a critical role in preventing HSV-1 reactivation from TG and subsequent virus shedding in tears that trigger recurrent corneal herpetic disease. The CXC chemokine ligand 10 (CXCL10)/CXC chemokine receptor 3 (CXCR3) chemokine pathway promotes T cell immunity to many viral pathogens, but its importance in CD8 T cell immunity to recurrent herpes has been poorly elucidated. In this study, we determined how the CXCL10/CXCR3 pathway affects TG- and cornea-resident CD8 T cell responses to recurrent ocular herpesvirus infection and disease using a well-established murine model in which HSV-1 reactivation was induced from latently infected TG by UV-B light. Following UV-B-induced HSV-1 reactivation, a significant increase in both the number and function of HSV-specific CXCR3 CD8 T cells was detected in TG and corneas of protected C57BL/6 (B6) mice, but not in TG and corneas of nonprotected CXCL10 or CXCR3 deficient mice. This increase was associated with a significant reduction in both virus shedding and recurrent corneal herpetic disease. Furthermore, delivery of exogenous CXCL10 chemokine in TG of CXCL10 mice, using the neurotropic adeno-associated virus type 8 (AAV8) vector, boosted the number and function of effector memory CD8 T cells (T) and tissue-resident memory CD8 T cells (T), but not of central memory CD8 T cells (T), locally within TG, and improved protection against recurrent herpesvirus infection and disease in CXCL10 deficient mice. These findings demonstrate that the CXCL10/CXCR3 chemokine pathway is critical in shaping CD8 T cell immunity, locally within latently infected tissues, which protects against recurrent herpesvirus infection and disease. We determined how the CXCL10/CXCR3 pathway affects CD8 T cell responses to recurrent ocular herpesvirus infection and disease. Using a well-established murine model, in which HSV-1 reactivation in latently infected trigeminal ganglia was induced by UV-B light, we demonstrated that lack of either CXCL10 chemokine or its CXCR3 receptor compromised the mobilization of functional CD8 T and CD8 T cells within latently infected trigeminal ganglia following virus reactivation. This lack of T cell mobilization was associated with an increase in recurrent ocular herpesvirus infection and disease. Inversely, augmenting the amount of CXCL10 in trigeminal ganglia of latently infected CXCL10-deficient mice significantly restored the number of local antiviral CD8 T and CD8 T cells associated with protection against recurrent ocular herpes. Based on these findings, a novel "prime/pull" therapeutic ocular herpes vaccine strategy is proposed and discussed.
单纯疱疹病毒1型(HSV-1)在三叉神经节(TG)的感觉神经元内建立潜伏感染。HSV特异性记忆CD8 T细胞在预防HSV-1从TG重新激活以及随后泪液中的病毒脱落从而引发复发性角膜疱疹疾病方面发挥着关键作用。CXC趋化因子配体10(CXCL10)/CXC趋化因子受体3(CXCR3)趋化因子途径促进T细胞对许多病毒病原体的免疫,但它在CD8 T细胞对复发性疱疹的免疫中的重要性尚未得到充分阐明。在本研究中,我们使用一个成熟的小鼠模型,通过紫外线B(UV-B)光诱导潜伏感染的TG中的HSV-1重新激活,来确定CXCL10/CXCR3途径如何影响TG和角膜驻留的CD8 T细胞对复发性眼部疱疹病毒感染和疾病的反应。在UV-B诱导的HSV-1重新激活后,在受保护的C57BL/6(B6)小鼠的TG和角膜中检测到HSV特异性CXCR3 CD8 T细胞的数量和功能显著增加,但在未受保护的CXCL10或CXCR3缺陷小鼠的TG和角膜中未检测到。这种增加与病毒脱落和复发性角膜疱疹疾病的显著减少相关。此外,使用嗜神经性8型腺相关病毒(AAV8)载体在CXCL10小鼠的TG中递送外源性CXCL10趋化因子,可增强效应记忆CD8 T细胞(T)和组织驻留记忆CD8 T细胞(T)的数量和功能,但不增强中枢记忆CD8 T细胞(T)的数量和功能,在TG局部增强,并改善CXCL10缺陷小鼠对复发性疱疹病毒感染和疾病的保护。这些发现表明,CXCL10/CXCR3趋化因子途径在潜伏感染组织局部塑造CD8 T细胞免疫方面至关重要,可预防复发性疱疹病毒感染和疾病。我们确定了CXCL10/CXCR3途径如何影响CD8 T细胞对复发性眼部疱疹病毒感染和疾病的反应。使用一个成熟的小鼠模型,其中潜伏感染的三叉神经节中的HSV-1重新激活由UV-B光诱导,我们证明缺乏CXCL10趋化因子或其CXCR3受体损害了病毒重新激活后潜伏感染的三叉神经节内功能性CD8 T和CD8 T细胞的动员。这种T细胞动员的缺乏与复发性眼部疱疹病毒感染和疾病的增加相关。相反,在潜伏感染的CXCL10缺陷小鼠的三叉神经节中增加CXCL10的量显著恢复了与预防复发性眼部疱疹相关的局部抗病毒CD8 T和CD8 T细胞的数量。基于这些发现,提出并讨论了一种新型的“启动/拉动”治疗性眼部疱疹疫苗策略。